Drugs

Stephen V Liu: Many updates in the 1.2024 National Comprehensive Cancer Network (NCCN) NSCLC guidelines

Photo from Stephen V Liu/X

Jan 16, 2024, 05:48

Stephen V Liu: Many updates in the 1.2024 National Comprehensive Cancer Network (NCCN) NSCLC guidelines

Stephen V Liu, Director of Thoracic Oncology and Developmental Therapeutics at Lombardi Comprehensive Cancer Center, posted on X/Twitter:

“Many updates in the 1.2024 National Comprehensive Cancer Network (NCCN) NSCLC guidelines including:
– amivantamab + carbo/pem preferred 1L for EGFR exon 20 (PAPILLON)
– amivantamab + carbo/pem for EGFR post osimertinib (MARIPOSA2)
– repotrectinib for 1L ROS1 (TRIDENT)
– atezolizumab monotherapy for PS3 (IPSOS).”

Source: Stephen V Liu/X

Amivantamab atezolizumab cancer EGFR National Comprehensive Cancer Network NCCN guidelines OncoDaily Oncology osimertinib Repotrectinib ROS1 Stephen V Liu

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Bispecific Antibody M701 Offers a Novel Treatment Option for Malignant Ascites

Special Coverage